How have KRBP shares performed in 2024?

Kiromic BioPharma's stock was trading at $0.87 at the start of the year. Since then, KRBP stock has increased by 187.4% and is now trading at $2.50. View the best growth stocks for 2024 here .

When is Kiromic BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our KRBP earnings forecast .

How were Kiromic BioPharma's earnings last quarter?

Kiromic BioPharma, Inc. (NASDAQ:KRBP) issued its quarterly earnings results on Monday, March, 18th. The company reported ($4.16) earnings per share for the quarter.

When did Kiromic BioPharma's stock split?

Kiromic BioPharma shares reverse split on the morning of Monday, March 13th 2023. The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Kiromic BioPharma IPO?

Kiromic BioPharma (KRBP) raised $16 million in an initial public offering on Friday, October 16th 2020. The company issued 1,200,000 shares at $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Paulson Investment Company was co-manager.

How do I buy shares of Kiromic BioPharma?

Shares of KRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KRBP

Kiromic BioPharma (KRBP) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free KRBP Stock Alerts

$2.50

+0.20 (+8.70%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.50
▼
$2.50
50-Day Range: $1.49
▼
$3.46
52-Week Range: $0.16
▼
$8.97

Volume: 834 shs
Average Volume: 8,650 shs
Market Capitalization: $3.23 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Kiromic BioPharma alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Kiromic BioPharma Stock (NASDAQ:KRBP)

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

KRBP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KRBP Stock News Headlines

April 10, 2024 | msn.com

Kiromic BioPharma files to withdraw registration statement

April 2, 2024 | businesswire.com

Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 19, 2024 | finance.yahoo.com

Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial

March 19, 2024 | businesswire.com

Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial

March 1, 2024 | businesswire.com

Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

February 28, 2024 | finance.yahoo.com

Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th

February 28, 2024 | businesswire.com

Kiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7th

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 14, 2024 | finance.yahoo.com

Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

February 14, 2024 | businesswire.com

Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

January 29, 2024 | finance.yahoo.com

Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

January 5, 2024 | finance.yahoo.com

Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial

December 14, 2023 | finance.yahoo.com

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer

November 16, 2023 | finance.yahoo.com

Kiromic BioPharma Announces Uplisting to OTCQB Market

November 9, 2023 | finance.yahoo.com

Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center

November 1, 2023 | morningstar.com

Kiromic BioPharma Inc Ordinary Shares

October 23, 2023 | finance.yahoo.com

Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement

September 15, 2023 | uk.investing.com

Staidson Beijing Biopharma (300204)

September 13, 2023 | finance.yahoo.com

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14

July 24, 2023 | finance.yahoo.com

Kiromic BioPharma Welcomes Two New Directors to its Board

June 30, 2023 | marketwatch.com

Kiromic Biopharma Shares Down 12% After Stock Offering Prospectus

June 10, 2023 | bizjournals.com

Founder of multibillion-dollar drug developer Array BioPharma leads Boulder oncology startup in $54M financing round

June 10, 2023 | finance.yahoo.com

KRBP - Kiromic BioPharma, Inc.

June 8, 2023 | theglobeandmail.com

Instrument Name Kiromic Biopharma Inc Instrument Symbol (KRBP-Q)

May 3, 2023 | finance.yahoo.com

What's Going On With Kiromic BioPharma Stock Wednesday

May 1, 2023 | finance.yahoo.com

Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer

See More Headlines

Receive KRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:KRBP
CUSIP: N/A
CIK: 1792581
Web: www.kiromic.com
Phone: 832-968-4888
Fax: N/A
Employees: 35
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($15.07)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,950,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -125.75%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.22
Quick Ratio: 0.22

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($7.25) per share
Price / Book: -0.32

Miscellaneous

Outstanding Shares: 1,290,000
Free Float: 1,246,000
Market Cap: $2.97 million
Optionable: Not Optionable
Beta: 2.00

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Brian Hungerford (Age 48)
Chief Financial Officer
Comp: $160.69k
Dr. Leonardo Mirandola Ph.D. (Age 42)
Chief Scientific Officer & Interim COO
Comp: $383.32k
Dr. Scott Dahlbeck M.D. (Age 62)
Pharm.D., PharmD, Chief of Staff
Comp: $359.08k

Key Competitors

View All Competitors

KRBP Stock Analysis - Frequently Asked Questions

How have KRBP shares performed in 2024?: Kiromic BioPharma's stock was trading at $0.87 at the start of the year. Since then, KRBP stock has increased by 187.4% and is now trading at $2.50.
View the best growth stocks for 2024 here.
When is Kiromic BioPharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our KRBP earnings forecast.
How were Kiromic BioPharma's earnings last quarter?: Kiromic BioPharma, Inc. (NASDAQ:KRBP) issued its quarterly earnings results on Monday, March, 18th. The company reported ($4.16) earnings per share for the quarter.
When did Kiromic BioPharma's stock split?: Kiromic BioPharma shares reverse split on the morning of Monday, March 13th 2023. The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Kiromic BioPharma IPO?: Kiromic BioPharma (KRBP) raised $16 million in an initial public offering on Friday, October 16th 2020. The company issued 1,200,000 shares at $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Paulson Investment Company was co-manager.
How do I buy shares of Kiromic BioPharma?: Shares of KRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRBP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kiromic BioPharma (KRBP) Stock Price, News & Analysis

About Kiromic BioPharma Stock (NASDAQ:KRBP)

KRBP Stock Price History

KRBP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

KRBP Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info